BioMarin Pharmaceutical

BMRNintermediary

BioMarin Pharmaceutical is a leader in rare-disease therapeutics with a portfolio of enzyme replacement therapies and the breakthrough growth drug Voxzogo for achondroplasia. Its Roctavian gene therapy for hemophilia A represents a one-time curative approach.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($2.8B)

Datos estáticos (cargando finanzas en tiempo real…)

Enzyme Replacement Therapies (45%)

Voxzogo (30%)

Roctavian & Other (15%)

Royalties & Collaborations (10%)

Composición de segmentos y clientes principales

Detalles del producto

Voxzogo (vosoritide)30%

C-type natriuretic peptide analog for achondroplasia in children

Roctavian (AAV gene therapy)10%

Gene therapy for severe hemophilia A

Enzyme Replacement Therapies45%

Naglazyme, Vimizim, and Palynziq for lysosomal storage disorders and PKU

Relaciones en la Cadena de Suministro

Competidores

Regeneron Pharmaceuticals

Rare disease biologics

Impacto: Limited overlap in rare disease

Pfizer Inc.

Gene therapy platforms

Impacto: Competing in gene therapy

Novo Nordisk

Rare blood disorders

Impacto: Competing in hemophilia

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de BioMarin Pharmaceutical impulsado por IA.

Información de la Empresa

Sede Central

San Rafael, California, USA

Fundación

1997

Empleados

4,200+

Sitio Web

biomarin.com

Estado del sector — 제약 / 바이오

Noticias del sector